Form 4: Vor Biopharma Director Fouad Namouni Granted 30,000 Stock Options

Fouad Namouni, a Director at Vor Biopharma Inc., was granted 30,000 stock options with an exercise price of $0.1868 as part of the company's non-employee director compensation policy.

Summary

• Fouad Namouni, a Director of Vor Biopharma Inc. (VOR), acquired 30,000 stock options on May 22, 2025.
• The stock options have an exercise price of $0.1868 per share.
• These options are set to expire on May 21, 2035.
• The grant was made pursuant to the Issuer's non-employee director compensation policy.
• The shares underlying the option will vest and become exercisable on the earlier of May 22, 2026, or the Issuer's next annual meeting of stockholders following the grant date, subject to Mr. Namouni's continued service as a director.

Sentiment

Score: 7

Explanation: The filing reports a routine grant of stock options to a director as part of compensation, which is generally viewed positively as it aligns management interests with shareholders and is a standard corporate governance practice.

Positives

• The grant of stock options to Director Fouad Namouni aligns his interests with those of shareholders, incentivizing long-term performance and value creation.
• The transaction is part of a standard non-employee director compensation policy, indicating a structured and transparent approach to executive incentives.

Negatives

• No direct negatives are identified in this Form 4 filing, as it reports a routine acquisition of options as part of compensation.

Risks

• The vesting of the granted stock options is contingent upon Fouad Namouni's continued service as a director through the specified vesting date.

Future Outlook

The stock options granted to Director Fouad Namouni are expected to vest on the earlier of May 22, 2026, or the company's next annual meeting of stockholders, provided he continues his service as a director.

Management Comments

• No specific management comments or direct quotes are provided in this Form 4 filing, as it is a statutory disclosure of an insider transaction.

Industry Context

The granting of stock options to non-employee directors is a common and widely accepted practice across various industries, including the biopharmaceutical sector. This method of compensation is used to attract and retain qualified board members, aligning their financial interests with the long-term performance and strategic goals of the company.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard compensation practice in the biotechnology and pharmaceutical sectors, comparable to similar arrangements at companies like CRISPR Therapeutics AG (CRSP) or Editas Medicine, Inc. (EDIT), which also utilize equity incentives to align director interests with company performance.
• The specific value and vesting schedule are typical for such roles, reflecting industry norms for attracting and retaining qualified board members and incentivizing long-term commitment.

Related Party Transactions

• The grant of 30,000 stock options to Fouad Namouni, a director of Vor Biopharma Inc., constitutes a related party transaction as it involves compensation to a member of the company's board of directors.

Stakeholder Impact

• **Shareholders:** The grant of stock options to a director aims to align their long-term interests with shareholder value creation, potentially leading to improved company performance.
• **Employees:** While not directly impacting all employees, such compensation practices for directors can influence the overall compensation philosophy and incentive structures within the company.

Next Steps

• The stock options will vest on the earlier of May 22, 2026, or the Issuer's next annual meeting of stockholders, contingent on Fouad Namouni's continued service as a director.

Key Dates

Keywords

Vor Biopharma, VOR, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Biopharma, Pharmaceutical